ProCE Banner Activity

Expert Insights on Seminal Data Presented at the 2023 IGCS Annual Meeting Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

Conference Coverage
Clinical Thought

Did you miss the seminal data presented for endometrial, ovarian, and cervical cancers at IGCS 2023? Read this expert commentary to get the latest insights.

Released: December 11, 2023

Share

Faculty

Keiichi Fujiwara

Keiichi Fujiwara, MD, PhD

Professor of Gynecologic Oncology
Saiama Medical University International Medical Center
Hidaka, Japan
Professor of OBGYN
International University of Health and Welfare
Narita, Japan

Brian Slomovitz

Brian Slomovitz, MD, MS, FACOG

Director
Gynecologic Oncology
Mount Sinai Medical Center
Professor 
Obsterics and Gynecology 
Florida International University
Member, Board of Directors 
GOG Foundation
Uterine Cancer Lead 
GOG Partners
Miami, Florida

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab and Seagen.

AstraZeneca

Genmab

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Novocure

Seagen

Disclosure

Primary Author

Keiichi Fujiwara, MD, PhD

Professor of Gynecologic Oncology
Saiama Medical University International Medical Center
Hidaka, Japan
Professor of OBGYN
International University of Health and Welfare
Narita, Japan

Keiichi Fujiwara, MD, PhD: consultant/advisor/speaker: Genmab, Sanofi, Seagen, Takeda.

Brian Slomovitz, MD, MS, FACOG

Director
Gynecologic Oncology
Mount Sinai Medical Center
Professor 
Obsterics and Gynecology 
Florida International University
Member, Board of Directors 
GOG Foundation
Uterine Cancer Lead 
GOG Partners
Miami, Florida

Brian Slomovitz, MD, MS FACOG: consultant/advisor/speaker: AstraZeneca, Clovis, Eisai, Genmab, Gilead, GlaxoSmithKline, Merck, Novartis, Novocure, Regeneron, Seagen.